08.21.17
Due to a recent surge in new oncology drugs entering the market, standards of cancer care are shifting at a quickening pace, leading some pharma companies to react to these changes mid-development. For instance, if a pharma company has a drug in clinical trials, but a competitor beats them to market, what do they do?
In this Q&A, we spoke with Andrew Zupnick, Ph.D., Vice President, Oncology Strategy of Novella Clinical to provide insights into the factors behind the rapid pace of new drug approvals, the implications for pharma companies in this crowded field, and how they can succeed in this hyper-competitive landscape.
Contract Pharma: What do you attribute to so many new drugs being approved?
Andrew Zupnick: We are currently in an era where our understanding of the biology behind cancer has aligned with improvements in technology to help spur the development of smarter therapies that can specifical
In this Q&A, we spoke with Andrew Zupnick, Ph.D., Vice President, Oncology Strategy of Novella Clinical to provide insights into the factors behind the rapid pace of new drug approvals, the implications for pharma companies in this crowded field, and how they can succeed in this hyper-competitive landscape.
Contract Pharma: What do you attribute to so many new drugs being approved?
Andrew Zupnick: We are currently in an era where our understanding of the biology behind cancer has aligned with improvements in technology to help spur the development of smarter therapies that can specifical
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
